Anti-Rabies Serum Market Report 2025

This anti-rabies serum market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The anti-rabies serum market size has grown strongly in recent years. It will grow from $1.42 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to growth in animal populations, expansion of vaccination programs, improved diagnostic techniques, increased travel and migration, and rising public health initiatives, rising incidence of wildlife encounters.

The anti-rabies serum market size is expected to see strong growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to the rising incidence of animal bites, increased funding for rabies research, rising awareness of zoonotic diseases, improvement in serum storage and handling, and enhanced support for rabies control programs. Major trends in the forecast period include the development of new serum formulations, advancements in healthcare infrastructure, technological advancements in serum production, the development of alternative delivery systems, and the development of rapid diagnostic kits.

The growing incidence of dog bites is expected to drive the expansion of the anti-rabies serum market. Dog bites, which can range from minor scratches to severe injuries, pose significant health risks including infections and the potential transmission of diseases such as rabies. Effective prevention and prompt medical treatment are crucial for managing these risks. The increasing frequency of dog bites is attributed to factors such as urbanization, which leads to more interactions between people and dogs, a higher number of unrestrained or poorly trained dogs, and a lack of awareness or education about dog behavior and bite prevention. Consequently, the rising prevalence of dog bites has boosted the demand for anti-rabies serum, as timely administration is essential to prevent the onset of rabies in those exposed to potentially infected animals. For example, in 2023, the American Veterinary Medical Association reported that the average cost for dog bite insurance claims was $58,545, with insurers paying out $1.12 billion in liability claims related to dog bites and other dog-related injuries. Dog bite claims increased by nearly 10% in 2023, highlighting the growing demand for anti-rabies serum.

Major companies in the anti-rabies serum market are forming strategic partnerships to enhance product development and broaden their market reach. Strategic partnerships involve leveraging each company's strengths and resources to achieve mutual benefits and success. For example, in July 2023, Kedrion S.p.A, a biopharmaceutical company based in the US, partnered with Kamada, an Israeli biopharmaceutical firm, to distribute KEDRAB (Rabies Immune Globulin [Human]) in the United States. This collaboration has been crucial in co-developing and licensing the product in the U.S. while also promoting awareness of the disease. Their joint efforts have contributed to protecting individuals exposed to rabid animal bites from serious and potentially life-threatening conditions.

In May 2022, Ceva Santé Animale, a French veterinary pharmaceutical company, acquired Artemis Technologies Inc. for an undisclosed amount. This acquisition enhances Ceva's rabies portfolio and strengthens its market presence in North America. Artemis Technologies Inc., based in Canada, provides a rabies glycoprotein recombinant oral vaccine.

Major companies operating in the anti-rabies serum market are Merck & Co Inc., Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, HCX Pharmaceuticals LLP, Intas Pharmaceuticals Ltd, Bavarian Nordic AS, Serum Institute of India Pvt Ltd., Bharat Serums And Vaccines Limited, Indian Immunologicals Ltd., Bharat Biotech., National Institute of Health Islamabad, ViNS Bioproducts Ltd., Shanghai Serum Bio-technology, Premium Serums and Vaccines Pvt Ltd., Congruent Pharmachem, Haffkine Bio Pharmaceutical Corporation Limited, LEXICARE PHARMA PVT. LTD., Avin Darou, Central Research Institute Kasauli, Vigilomed Pharmaceuticals.

North America was the largest region in the anti-rabies serum market in 2024. The regions covered in the anti-rabies serum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-rabies serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anti-rabies serum, also known as rabies immune globulin (RIG), is a medical treatment that provides immediate passive immunity against the rabies virus. It is used for individuals exposed to the virus, typically through bites or scratches from potentially rabid animals, and is administered alongside the rabies vaccine. The serum contains antibodies that neutralize the virus, helping to prevent the development of rabies, a fatal disease once symptoms appear.

The main types of anti-rabies serum are human anti-rabies immunoglobulin and equine anti-rabies immunoglobulin. Human rabies immune globulin (HRIG) is derived from the blood plasma of human donors who have been immunized against rabies and is preferred for its lower risk of allergic reactions and better compatibility with human patients. This serum is available in various dosage forms, including vials and prefilled syringes, and is administered either intravenously or intramuscularly. It is used by a range of end-users, including hospitals, clinics, and veterinary hospitals.

The anti-rabies serum market research report is one of a series of new reports that provides anti-rabies serum market statistics, including anti-rabies serum industry global market size, regional shares, competitors with a anti-rabies serum market share, detailed anti-rabies serum market segments, market trends and opportunities, and any further data you may need to thrive in the anti-rabies serum industry. This anti-rabies serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-rabies serum market consists of sales of rabies monoclonal antibodies, rabies immune globulin (RIG) combination products, and human rabies immune globulin (HRIG). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.